| Literature DB >> 34541261 |
Lara H Sattgast1, Adam J Branscum2, Vanessa A Jimenez3, Natali Newman3, Kathleen A Grant3, Russell T Turner1, Urszula T Iwaniec1.
Abstract
Development of optimal bone mass during early adulthood is determined by the balance between bone formation and resorption. The utility of minimally invasive biomarkers for monitoring bone turnover balance in maturing non-human primates has received limited attention. This study evaluated the biological variation of osteocalcin (a marker of bone formation), carboxyterminal cross-linking telopeptide of type 1 collagen (CTX, a marker of bone resorption), and the ratio of osteocalcin to CTX (reflecting bone turnover balance), in 136 rhesus and cynomolgus macaques aged 3.8-11.6 years. In a subsample of the animals (n = 28), blood samples were collected at monthly intervals over 4 months. Between-subject analysis revealed that there were no sex or species differences for CTX. Osteocalcin and the ratio of osteocalcin to CTX were higher in males than in females, and in rhesus macaques than in cynomolgus macaques. There were no changes in osteocalcin, CTX, or the ratio of osteocalcin to CTX across 4 months for any of the groups. In contrast, there was considerable within-subject variation in osteocalcin and CTX concentrations. However, differences in values exhibited no discernible pattern, suggesting that within-subject variation can be reduced by averaging repeat measurements. In summary, the data provide reference values for male and female rhesus and cynomolgus macaques and support the utility of osteocalcin and CTX as biomarkers to monitor bone turnover at the population level.Entities:
Keywords: Bone; Bone turnover; Monkey; Osteocalcin; c-Terminal telopeptide
Year: 2021 PMID: 34541261 PMCID: PMC8436065 DOI: 10.1016/j.bonr.2021.101126
Source DB: PubMed Journal: Bone Rep ISSN: 2352-1872
Age and plasma concentrations of biochemical markers of all monkeys at a single time point.
| Rhesus macaque | Cynomolgus macaque | Rhesus vs. cynomolgus | ||||||
|---|---|---|---|---|---|---|---|---|
| Male (N = 63) | Female (N = 17) | P | Male (N = 34) | Female (N = 22) | P | P (male) | P (female) | |
| Age (years) | 5.7 (95% CI: 5.3, 6.0) | 4.9 (95% CI: 4.4, 5.3) | 0.027 | 6.4 (95% CI: 6.3, 6.5) | 8.3 (95% CI: 7.5, 9.2) | <0.0001 | 0.015 | <0.0001 |
| Osteocalcin (ng/ml) | 27.6 (95% CI: 24.6, 30.7) | 18.7 (95% CI: 14.7, 22.7) | 0.005 | 18.0 (95% CI: 14.8, 21.3) | 12.0 (95% CI: 10.1, 14.0) | 0.007 | <0.0001 | 0.002 |
| CTX (ng/ml) | 1.65 (95% CI: 1.50, 1.80) | 1.46 (95% CI: 1.22, 1.70) | 0.237 | 1.53 (95% CI: 1.38, 1.68) | 1.38 (95% CI: 1.15, 1.61) | 0.244 | 0.407 | 0.624 |
| Osteocalcin:CTX ratio | 17.5 (95% CI: 15.7, 19.2) | 13.2 (95% CI: 10.8, 15.6) | 0.021 | 11.9 (95% CI: 10.1, 13.8) | 9.2 (95% CI: 7.7, 10.8) | 0.042 | 0.0004 | 0.004 |
Data presented are means and 95% confidence intervals (CI).
p-Value for comparison of males vs. females within each species (e.g., male vs. female rhesus macaques; male vs. female cynomolgus macaques).
p-Value for comparison of male rhesus macaques vs. male cynomolgus macaques.
p-Value for comparison of female rhesus macaques vs. female cynomolgus macaques.
Fig. 1Blood levels of osteocalcin, CTX, and the ratio of osteocalcin to CTX among male rhesus macaques (A–C, respectively, n = 63), female rhesus macaques (D–F, respectively, n = 17), male cynomolgus macaques (G–I, respectively, n = 34), and female cynomolgus macaques (J–L, respectively, n = 22). The biomarkers were measured once for each animal and each point represents a single measurement for a given animal. Linear regression lines were fit for male rhesus macaques and female cynomolgus macaques. Mean values of each biomarker were compared across sex for subgroups where there was overlap in age (as demarcated with dotted lines): 1) rhesus macaques aged 3.7–6.1 years (N = 52 male and 17 female), and 2) cynomolgus macaques aged 6–7 years (N = 30 male and 11 female).
Age and plasma concentrations of biochemical markers in a subset of monkeys collected over four monthly intervals.
| Rhesus macaque | Cynomolgus macaque | Rhesus vs. cynomolgus | ||||||
|---|---|---|---|---|---|---|---|---|
| Male (N = 11) | Female (N = 3) | P | Male (N = 6) | Female (N = 8) | P | P (male) | P (female) | |
| Age (years) | 5.1 (95% CI: 4.9, 5.2) | 4.3 (95% CI: 4.3, 4.4) | <0.0001 | 6.7 (95% CI: 6.7, 6.8) | 10.2 (95% CI: 9.7, 10.7) | <0.0001 | <0.0001 | <0.0001 |
| Osteocalcin (ng/ml) | 37.1 (95% CI: 34.1, 40.2) | 19.5 (95% CI: 14.6, 24.4) | <0.0001 | 20.7 (95% CI: 16.8, 24.6) | 10.5 (95% CI: 8.9, 12.2) | <0.0001 | <0.0001 | <0.0001 |
| CTX (ng/ml) | 1.69 (95% CI: 1.56, 1.82) | 1.49 (95% CI: 1.27, 1.71) | 0.153 | 1.38 (95% CI: 1.23, 1.53) | 1.02 (95% CI: 0.91, 1.13) | <0.0001 | 0.005 | <0.0001 |
| Osteocalcin:CTX ratio | 22.7 (95% CI: 21.0, 24.5) | 12.8 (95% CI: 10.8, 14.8) | <0.0001 | 15.0 (95% CI: 12.5, 17.4) | 10.9 (95% CI: 9.0, 12.9) | 0.009 | <0.0001 | 0.265 |
Data presented are means and 95% confidence intervals (CI).
p-Value for comparison of males vs. females within each species (e.g., male vs. female rhesus macaques; male vs. female cynomolgus macaques).
p-Value for comparison of male rhesus macaques vs. male cynomolgus macaques.
p-Value for comparison of female rhesus macaques vs. female cynomolgus macaques.
Fig. 2Longitudinal levels of osteocalcin (A–B), CTX (C–D), and the ratio of osteocalcin to CTX (E–F) over 4 monthly intervals in male (n = 11) and female (n = 3) rhesus macaques. Data are presented by age (years) at time of sample collection. There is considerable variability in biomarker values for individual monkeys over each timepoint and there was no discernible pattern in this variability.
Fig. 3Longitudinal levels of osteocalcin (A–B), CTX (C–D), and the ratio of osteocalcin to CTX (E–F) over 4 monthly intervals in male (n = 6) and female (n = 8) cynomolgus macaques. Data are presented by age (years) at time of sample collection. There is considerable variability in biomarker values for individual monkeys over each timepoint and there was no discernible pattern in this variability.
Fig. 4Longitudinal levels of osteocalcin (A–B), CTX (C–D), and the ratio of osteocalcin to CTX (E–F) over 4 monthly intervals in male (n = 11) and female (n = 3) rhesus macaques. Data are presented by month of measurement and means were estimated using linear mixed models with 95% confidence intervals. The slope of each of the regression lines was nonsignificant, suggesting that the mean values of each biomarker did not change over the 4-month period at the population level. The mean and 95% confidence intervals for each regression line are included to the right of each graph.
Fig. 5Longitudinal levels of osteocalcin (A–B), CTX (C–D), and the ratio of osteocalcin to CTX (E–F) over 4 monthly intervals in male (n = 6) and female (n = 8) cynomolgus macaques. Data are presented by month of measurement and means were estimated using linear mixed models with 95% confidence intervals. The slope of each of the regression lines was nonsignificant, suggesting that the mean values of each biomarker did not change over the 4-month period at the population level. The mean and 95% confidence intervals for each regression line are included to the right of each graph.
Biological variance in male and female rhesus and cynomolgus macaques over four months.
| Rhesus macaque | Cynomolgus macaque | |||
|---|---|---|---|---|
| Male (N = 11) | Female (N = 3) | Male (N = 6) | Female (N = 8) | |
| Osteocalcin (ng/ml) | ||||
| CVI (%) | 8.2 to 53.3 | 14.6 to 34.5 | 8.1 to 37.6 | 5.3 to 42.6 |
| ICC | 0.19 (95% CI: 0.03, 0.45) | 0.54 (95% CI: 0.09, 0.93) | 0.81 (95% CI: 0.53, 0.95) | 0.59 (95% CI: 0.28, 0.86) |
| Within-subject variance | 0.40 (95% CI: 0.31, 0.50) | 0.28 (95% CI: 0.18, 0.44) | 0.24 (95% CI: 0.17, 0.33) | 0.25 (95% CI: 0.19, 0.34) |
| Between-subject variance | 0.19 (95% CI: 0.08, 0.45) | 0.30 (95% CI: 0.11, 0.80) | 0.48 (95% CI: 0.27, 0.88) | 0.31 (95% CI: 0.17, 0.54) |
| CTX (ng/ml) | ||||
| CVI (%) | 1.6 to 46.0 | 4.9 to 25.5 | 6.6 to 22.4 | 7.2 to 27.3 |
| ICC | 0.16 (95% CI: 0.02, 0.56) | 0.27 (95% CI: 0.01, 0.89) | 0.58 (95% CI: 0.23, 0.88) | 0.59 (95% CI: 0.27, 0.85) |
| Within-subject variance | 0.42 (95% CI: 0.33, 0.53) | 0.29 (95% CI: 0.18, 0.45) | 0.22 (95% CI: 0.16, 0.31) | 0.19 (95% CI: 0.14, 0.25) |
| Between-subject variance | 0.18 (95% CI: 0.07, 0.48) | 0.17 (95% CI: 0.04, 0.69) | 0.26 (95% CI: 0.14, 0.52) | 0.23 (95% CI: 0.13, 0.40) |
| Osteocalcin:CTX ratio | ||||
| CVI (%) | 4.1 to 40.3 | 10.3 to 25.3 | 13.5 to 46.4 | 6.1 to 50.5 |
| ICC | 0.55 (95% CI: 0.29, 0.41) | 0.41 (95% CI: 0.07, 0.85) | 0.67 (95% CI: 0.33, 0.91) | 0.51 (95% CI: 0.20, 0.82) |
| Within-subject variance | 0.22 (95% CI: 0.18, 0.28) | 0.20 (95% CI: 0.13, 0.32) | 0.26 (95% CI: 0.19, 0.36) | 0.29 (95% CI: 0.16, 0.54) |
| Between-subject variance | 0.25 (95% CI: 0.15, 0.41) | 0.15 (95% CI: 0.04, 0.49) | 0.38 (95% CI: 0.20, 0.71) | 0.29 (95% CI: 0.22, 0.38) |
Data presented are means and 95% confidence intervals (CI).